Insys Therapeutics, Inc., a specialty pharmaceutical company, announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme, the most common and most aggressive malignant primary brain tumor in humans. Glioblastoma can be difficult to treat because the tumors contain several different types of cells. Some cells may respond well to certain therapies, while others may not be affected at all. This is why the treatment plan for glioblastoma may combine several approaches.
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S.
While the therapeutic properties of cannabidiol are still being understood, it is clear that we are just at the cusp of understanding the possibilities of CBD as a treatment.